Free Trial
NASDAQ:CLYM

Climb Bio (CLYM) Stock Price, News & Analysis

Climb Bio logo
$1.30 -0.01 (-0.38%)
As of 10:02 AM Eastern

About Climb Bio Stock (NASDAQ:CLYM)

Key Stats

Today's Range
$1.30
$1.37
50-Day Range
$1.13
$1.53
52-Week Range
$1.05
$11.55
Volume
3,369 shs
Average Volume
315,874 shs
Market Capitalization
$87.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
Consensus Rating
Strong Buy

Company Overview

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

Climb Bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
49th Percentile Overall Score

CLYM MarketRank™: 

Climb Bio scored higher than 49% of companies evaluated by MarketBeat, and ranked 606th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Climb Bio has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Climb Bio has received no research coverage in the past 90 days.

  • Read more about Climb Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Climb Bio are expected to grow in the coming year, from ($1.57) to ($0.66) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Climb Bio is -0.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Climb Bio is -0.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Climb Bio has a P/B Ratio of 0.33. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Climb Bio's valuation and earnings.
  • Short Interest

    There is no current short interest data available for CLYM.
  • Dividend Yield

    Climb Bio does not currently pay a dividend.

  • Dividend Growth

    Climb Bio does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for CLYM.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Climb Bio this week, compared to 1 article on an average week.
  • Search Interest

    1 people have searched for CLYM on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Climb Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,571.00 in company stock.

  • Percentage Held by Insiders

    Only 3.20% of the stock of Climb Bio is held by insiders.

  • Percentage Held by Institutions

    69.76% of the stock of Climb Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Climb Bio's insider trading history.
Receive CLYM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Climb Bio and its competitors with MarketBeat's FREE daily newsletter.

CLYM Stock News Headlines

Climb Bio appoints Kim Cobleigh Drapkin, Bo Cumbo to board
Feds Just Admitted It—They Can Take Your Cash
Here’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousands of smart, forward-thinking individuals are making the move—out of the system and into real, untouchable assets. Because once your funds are frozen, it’s too late.
See More Headlines

CLYM Stock Analysis - Frequently Asked Questions

Climb Bio's stock was trading at $1.80 on January 1st, 2025. Since then, CLYM shares have decreased by 27.8% and is now trading at $1.30.
View the best growth stocks for 2025 here
.

Climb Bio, Inc. (NASDAQ:CLYM) issued its quarterly earnings results on Tuesday, March, 25th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.02.

Shares of CLYM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
3/25/2025
Today
4/25/2025
Next Earnings (Estimated)
5/21/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CLYM
Previous Symbol
NASDAQ:CLYM
Fax
N/A
Employees
9
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$10.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+669.2%
Consensus Rating
Strong Buy
Rating Score (0-4)
3.50
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-35,120,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$3.90 per share
Price / Book
0.33

Miscellaneous

Free Float
65,073,000
Market Cap
$87.72 million
Optionable
N/A
Beta
-0.10
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:CLYM) was last updated on 4/25/2025 by MarketBeat.com Staff
From Our Partners